Noctura 400 is a medical sleep mask that treats diabetic eye disease by shining a gentle green light into your eyes while you sleep. Made by PolyPhotonix, a UK-based company, it’s designed to slow or prevent the progression of diabetic retinopathy and diabetic macular edema, two common complications of diabetes that can lead to vision loss. It’s worth noting: if you were searching for “nocturia” (waking at night to urinate), that’s a different condition entirely, and we’ll briefly cover it at the end.
How the Noctura 400 Works
The mask looks like a standard fabric sleep mask, but it houses a plastic pod containing two small light-emitting panels. These panels produce a soft green glow at a very specific wavelength (around 502 nanometers) that passes through your closed eyelids and reaches the retina at the back of your eye.
The idea behind it comes down to what happens in your eyes during total darkness. When you sleep in a dark room, the light-sensing rod cells in your retina shift into a state called dark adaptation. In this mode, rod cells consume their maximum amount of oxygen. For people with diabetes, the tiny blood vessels supplying the retina are often already damaged and struggling to deliver enough oxygen. When rod cells ramp up their oxygen demand overnight, the resulting oxygen shortage triggers the body to produce a growth factor that causes blood vessels to leak fluid into the retina. Over time, this leads to swelling (macular edema) and progressive damage to the retinal blood vessels (retinopathy).
The Noctura 400’s green light keeps the rod cells gently stimulated throughout the night, preventing them from fully dark-adapting. This reduces their oxygen consumption and, in theory, breaks the cycle of overnight oxygen deprivation, abnormal blood vessel growth, and fluid leakage. Since dark adaptation really only happens during sleep, nighttime is the critical window the device targets.
Who It’s Designed For
The Noctura 400 is aimed at people with diabetes who have mild to moderate eye disease. Clinical evidence reviewed by the UK’s National Institute for Health and Care Excellence (NICE) suggests the mask may benefit patients with mild, non-proliferative diabetic retinopathy and diabetic macular edema. It may also help prevent these conditions from developing in people with diabetes who don’t yet show signs of eye damage.
There is currently no evidence supporting its use in advanced or proliferative diabetic retinopathy, the later stages where abnormal new blood vessels have already grown across the retina. The device is positioned as an option for earlier-stage disease, potentially slowing progression before more invasive treatments become necessary.
What the Clinical Evidence Shows
The largest trial, called CLEOPATRA, was a phase 3 randomized controlled study published in The Lancet Diabetes & Endocrinology. The trial tested whether preventing dark adaptation with the light mask could reduce or halt diabetic macular edema over 24 months. The underlying science was supported: rod cells do consume significantly more oxygen in darkness, and suppressing that demand should reduce stress on compromised retinal blood vessels.
Earlier studies showed some promising results. One found that treated eyes had reduced retinal swelling, fewer fluid-filled cysts within the retina, and improvements in visual acuity compared to untreated eyes in patients with mild diabetic retinopathy. A real-world observational study followed 26 patients with diabetic retinopathy and macular edema who wore the mask for one year, looking at how the device performed outside of tightly controlled trial conditions. Overall, NICE’s assessment described the evidence as providing a “limited indication” of benefit, noting that more data is needed.
How It Compares to Standard Treatments
The standard treatment for diabetic macular edema involves injections directly into the eye that block the growth factor responsible for blood vessel leakage. These injections are effective but require repeated clinic visits, often monthly at first, and many patients find them burdensome. Laser treatment is another established option.
The Noctura 400 works through a completely different approach. Rather than blocking the problematic growth factor after it’s already been produced, the mask aims to prevent the oxygen shortage that triggers its production in the first place. It’s a home-use, non-invasive device worn during sleep, which makes it far less burdensome than clinic-based treatments. The mask is not currently positioned as a replacement for injections or laser therapy in patients who already need them, but rather as a complementary tool or an option for earlier-stage disease where those treatments haven’t yet become necessary.
Availability and Regulatory Status
The Noctura 400 carries a CE mark and is registered with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). It has been listed on the NHS Part IX Drug Tariff, meaning it can be prescribed through the standard prescription route by GPs and other healthcare professionals in the UK. This listing made it more accessible to patients within the NHS system without requiring a specialist referral for the prescription itself.
Availability outside the UK is more limited. The device has not received FDA clearance in the United States, so American patients do not currently have access to it through their healthcare system.
What It’s Like to Use
You wear the mask each night while you sleep, similar to a regular sleep mask. The green light emitted through the panels is designed to be gentle enough not to prevent sleep, though adjusting to sleeping with any light stimulus takes some getting used to. The treatment is intended for ongoing, nightly use rather than a short course. In the real-world study, patients wore the mask consistently over 12 months, and the clinical trials tracked outcomes over 24 months, suggesting this is a long-term commitment rather than a quick fix.
Because the light needs to reach your retina through closed lids, proper positioning of the mask matters. The device houses its light panels behind acrylic lenses to direct the glow appropriately.
Did You Mean Nocturia?
If you actually searched for “nocturia,” you’re looking for information about a different condition. Nocturia is the medical term for waking up one or more times during the night to urinate. It becomes clinically bothersome when you’re getting up two or more times per night, and it’s one of the most common and disruptive urinary symptoms in adults.
Despite often being grouped with bladder or prostate problems, nocturia isn’t always caused by a lower urinary tract issue. The most common driver is actually nighttime overproduction of urine, called nocturnal polyuria, which can stem from heart, kidney, or lung conditions. It can also result from simply drinking too much fluid before bed, taking certain medications, or age-related changes in hormone production that normally concentrate urine overnight. If nocturia is disrupting your sleep regularly, it’s worth bringing up with a healthcare provider, as the underlying cause determines the right approach to managing it.